AstraZeneca reported an operating cash flow of 14.58 billion U.S. dollars in 2025. AstraZeneca is one of the leading global biopharmaceutical companies. The company focuses mainly on manufacturing medicine in oncology, cardiovascular, and metabolic diseases.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
U.S. Securities and Exchange Commission, & AstraZeneca. (February 18, 2026). Operating cash flow of AstraZeneca from 2015 to 2025 (in billion U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 15, 2026, from /statistics/1660834/astrazeneca-s-operating-cash-flow/
U.S. Securities and Exchange Commission, und AstraZeneca. "Operating cash flow of AstraZeneca from 2015 to 2025 (in billion U.S. dollars)." Chart. February 18, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 15, 2026. /statistics/1660834/astrazeneca-s-operating-cash-flow/
U.S. Securities and Exchange Commission, AstraZeneca. (2026). Operating cash flow of AstraZeneca from 2015 to 2025 (in billion U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 15, 2026. /statistics/1660834/astrazeneca-s-operating-cash-flow/
U.S. Securities and Exchange Commission, and AstraZeneca. "Operating Cash Flow of Astrazeneca from 2015 to 2025 (in Billion U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 18 Feb 2026, /statistics/1660834/astrazeneca-s-operating-cash-flow/
U.S. Securities and Exchange Commission & AstraZeneca, Operating cash flow of AstraZeneca from 2015 to 2025 (in billion U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1660834/astrazeneca-s-operating-cash-flow/ (last visited July 15, 2026)
Operating cash flow of AstraZeneca from 2015 to 2025 (in billion U.S. dollars) [Graph], U.S. Securities and Exchange Commission, & AstraZeneca, February 18, 2026. [Online]. Available: /statistics/1660834/astrazeneca-s-operating-cash-flow/
